RecruitingRecruiting
Efficacy of an EMDR App for PTSD and SUD
NCT07146633 · Centre for Addiction and Mental Health
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Efficacy and Feasibility of Autonomous Eye Movement Desensitization and Reprocessing (A-EMDR) for Patients With Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders
About this study
This is an open-label pilot randomized, wait-list controlled trial evaluating A-EMDR for the treatment of PTSD in patients with SUD for four weeks with a follow up at week eight. Primary outcomes will be measured at the end of the study (week 4) for both groups and at follow up (week 8) for the A-EMDR group.
Eligibility criteria
Inclusion Criteria:
* Aged 18-years old or older
* Fluent in English
* Diagnosed with PTSD by the PTSD Checklist for DSM-5 (PCL-5 past month version score \>32)
* Diagnosed with past-year substance use disorder other than caffeine by structured clinical interview for DSM-5 (SCID-5)
* Agrees not to participate in other treatments during the study duration (e.g., mindfulness, yoga, biofeedback, self-hypnosis or tai chi) except individuals who have been already on continuous therapies for at least three months
Exclusion Criteria:
* Diagnosis of a severe or unstable mental illness that precludes safe participation in the study by a healthcare practitioner such as acute psychosis or mania diagnosed by a healthcare practitioner
* Current suicidality risk as indicated during the conduct of the Columbia Suicide Severity Rating Scale (C-SSRS) (21) with concurrence after a study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes"
Study design
Enrollment target: 24 participants
Allocation: randomized
Masking: single
Age groups: adult, older_adult
Timeline
Starts: 2026-01-20
Estimated completion: 2027-01-30
Last updated: 2026-05-22
Interventions
Behavioral: A-EMDROther: Treatment as Usual (TAU)
Primary outcomes
- • Changes in PTSD symptoms and alcohol/drug consumption during 4 weeks of treatment. (From enrollment to the end of treatment at 4 weeks)
Sponsor
Centre for Addiction and Mental Health · other
All locations (1)
100 Stokes StRecruiting
Toronto, Ontario, Canada